Acting on Actionable Mutations in Metastatic Prostate Cancer

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2023 Apr 25

PMID 37098244

Authors

Catherine H Marshall

Affiliations

Soon will be listed here.

Abstract

Journal Journal of Clinical Oncology.Approximately a quarter of men with metastatic castration-resistant prostate cancer have genomic alterations within the homologous recombination repair pathway with poly (ADP-ribose) polymerase (PARP) inhibitors as corresponding treatment options. How to incorporate genomic information and associated therapeutic options into treatment decision making and sequencing of therapies in prostate cancer remains challenging. Men with alterations seem to derive the most benefit from PARP inhibitors, and although early treatment in combination with standard therapies has not yet shown an overall survival benefit, there may be other benefits to incorporating PARP inhibitors early for some men.

Citing Articles

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?.

Elias R, Antonarakis E Transl Cancer Res. 2023; 12(10):2448-2453.

PMID: 37969378 PMC: 10643943. DOI: 10.21037/tcr-23-1279.

References

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(24):2345-2357. DOI: 10.1056/NEJMoa2022485. View

Gillessen S, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A . Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022; 82(1):115-141. DOI: 10.1016/j.eururo.2022.04.002. View

McGrail D, Pilie P, Rashid N, Voorwerk L, Slagter M, Kok M . High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021; 32(5):661-672. PMC: 8053682. DOI: 10.1016/j.annonc.2021.02.006. View

Taza F, Holler A, Fu W, Wang H, Adra N, Albany C . Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2021; 5. PMC: 8575434. DOI: 10.1200/PO.21.00070. View

Yarchoan M, Albacker L, Hopkins A, Montesion M, Murugesan K, Vithayathil T . PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019; 4(6). PMC: 6482991. DOI: 10.1172/jci.insight.126908. View

Marcus L, Lemery S, Keegan P, Pazdur R . FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res. 2019; 25(13):3753-3758. DOI: 10.1158/1078-0432.CCR-18-4070. View

Clarke N, Armstrong A, Thiery-Vuillemin A, Oya M, Shore N, Loredo E . Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2024; 1(9):EVIDoa2200043. DOI: 10.1056/EVIDoa2200043. View

Ryan C, Ke X, Lafeuille M, Romdhani H, Kinkead F, Lefebvre P . Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. J Urol. 2021; 206(6):1420-1429. PMC: 8584208. DOI: 10.1097/JU.0000000000002121. View

Pritchard C, Mateo J, Walsh M, De Sarkar N, Abida W, Beltran H . Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016; 375(5):443-53. PMC: 4986616. DOI: 10.1056/NEJMoa1603144. View

10.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

11.

Abida W, Cheng M, Armenia J, Middha S, Autio K, Vargas H . Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2018; 5(4):471-478. PMC: 6459218. DOI: 10.1001/jamaoncol.2018.5801. View

12.

Stopsack K . Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. 2020; 79(4):442-445. PMC: 8403336. DOI: 10.1016/j.eururo.2020.09.024. View

13.

Marshall C, Imada E, Tang Z, Marchionni L, Antonarakis E . CDK12 inactivation across solid tumors: an actionable genetic subtype. Oncoscience. 2019; 6(5-6):312-316. PMC: 6650168. DOI: 10.18632/oncoscience.481. View

14.

Chi K, Rathkopf D, Smith M, Efstathiou E, Attard G, Olmos D . Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023; 41(18):3339-3351. PMC: 10431499. DOI: 10.1200/JCO.22.01649. View

15.

Pritchard C, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I . Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun. 2014; 5:4988. PMC: 4176888. DOI: 10.1038/ncomms5988. View

16.

Mohler J, Antonarakis E, Armstrong A, DAmico A, Davis B, Dorff T . Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(5):479-505. DOI: 10.6004/jnccn.2019.0023. View

17.

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 382(22):2091-2102. DOI: 10.1056/NEJMoa1911440. View

18.

Marshall C, Sokolova A, McNatty A, Cheng H, Eisenberger M, Bryce A . Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. 2019; 76(4):452-458. PMC: 6703974. DOI: 10.1016/j.eururo.2019.02.002. View

19.

Abida W, Patnaik A, Campbell D, Shapiro J, Bryce A, McDermott R . Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a or Gene Alteration. J Clin Oncol. 2020; 38(32):3763-3772. PMC: 7655021. DOI: 10.1200/JCO.20.01035. View